Viewing Study NCT05528458


Ignite Creation Date: 2025-12-25 @ 12:24 AM
Ignite Modification Date: 2026-01-08 @ 4:46 PM
Study NCT ID: NCT05528458
Status: RECRUITING
Last Update Posted: 2024-04-23
First Post: 2022-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Sponsor: Samsung Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module